<DOC>
	<DOCNO>NCT01586468</DOCNO>
	<brief_summary>Objectives To assess efficacy safety WF10 infusion treatment subject persistent allergic rhinitis . Study Design Randomized , double-blind , placebo-controlled , parallel-group , single-centre trial . Subjects 50 subject ( 25 per treatment group ) history persistent allergic rhinitis least 2 year prior enrolment positive allergen skin test . Subjects require minimum mean score ≥6 baseline Total Nasal Symptom Score ( TNSS ) ( mean score morning even reflective TNSS assessment 3 day prior randomization treatment . Treatments At first treatment visit ( T1 ) , subject comply inclusion exclusion criterion randomize one two treatment group : WF10 , placebo . Each individual treatment dose study drug solution 0.5 mL/kg body weight , dilute 500 mL saline solution . Treatment administer daily 5 consecutive day ( Visits T1-T5 ) via intravenous infusion .</brief_summary>
	<brief_title>PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . History persistent allergic rhinitis least 2 year prior enrolment . Concurrent history asthma permit . 2 . Positive allergen skin test relevant allergen ( ) , perform within previous 2 year prior enrolment . 3 . Mean score ≥6 baseline Total Nasal Symptom Score ( TNSS ) 4 . Screening laboratory value within normal range , except related primary disease , include eosinophil count , elevate glucose allow . 5 . Age 18 70 year , inclusive . 6 . The subject must able read understand German well enough answer question TNSS Mini Rhinoconjunctivitis Quality Life Questionnaire ( MiniRQLQ ) , without translation explanation . 7 . If female , subject : 1 . Can become pregnant surgically sterile ( hysterectomy tubal ligation ) , postmenopausal least 6 month prior screen visit . OR 2 . Is pregnant , negative pregnancy test screening ( confirm baseline visit ) , use acceptable method contraception low failure rate ( PEARL Index ) ( i.e . le 1 % per year ) use consistently correct ( include oral contraceptive , hormone implant , intrauterine device , , male sexual partner ( ) surgically sterile , abstinence ) . 8 . Except persistent allergic rhinitis , subject reasonably good health , determine discretion study investigator ( base physical examination electrocardiogram [ ECG ] result ) . 9 . The subject sign informed consent form . 1 . Nonallergic rhinitis , rhinitis medicamentosa , idiopathic rhinitis sinusitis . 2 . History nasal surgery 6 month prior enrolment . 3 . An upper respiratory sinus infection within 2 week prior enrolment . 4 . Presence severely deviate septum , septal perforation , structural nasal defect large nasal polyp cause obstruction . 5 . Use intramuscular glucocorticosteroids 12 week prior enrolment ; use oral , intravenous medium high daily dose inhaled glucocorticosteroids ( describe GINA guideline see App . III ) ) 4 week prior enrolment ; use topical ( nasal ocular ) glucocorticosteroids 2 week prior enrolment . . 6 . Use antiIgE antibody ( e.g . omalizumab ) 12 week prior enrolment . 7 . Use antileukotrienes ( e.g . montelukast ) 4 week prior enrolment . 8 . Unwillingness discontinue prohibit medication avoid use study ( see section 10.1.5 complete list prohibit medication ) . 9 . Severe haematopoetic , cardiovascular , hepatic , renal , neurological psychiatric disease . 10 . Glucose6phosphate dehydrogenase deficiency ( activity &lt; 60 % = &lt; WHO class 4 ) 11 . A female subject lactating . 12 . Planned travel outside study area first 22 day study . 13 . Any infirmity , disability geographical location would limit compliance protocol . 14 . A subject previously randomize study , receive least one dose study treatment withdrawn trial allow reenter . 15 . Use another investigational drug within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>